1-11 of 11
Nadine Besson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors

Clinical Trials & Observations
Hagop M. Kantarjian, Jorge E. Cortes, Dong-Wook Kim, H. Jean Khoury, Tim H. Brümmendorf, Kimmo Porkka, Giovanni Martinelli, Simon Durrant, Eric Leip, Virginia Kelly, Kathleen Turnbull, Nadine Besson, Carlo Gambacorti-Passerini
Journal: Blood
Blood (2014) 123 (9): 1309–1318.
https://doi.org/10.1182/blood-2013-07-513937
Published: 2014
Includes: Supplemental data
Journal Articles

Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib.

Jorge E. Cortes, MD, H. Jean Khoury, Jeff H Lipton, MD, Carlo Gambacorti-Passerini, Tim H Brümmendorf, Dong-Wook Kim, Eric Leip, Virginia Kelly, Nadine Besson, Kathleen Turnbull, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2012) 120 (21): 2793.
https://doi.org/10.1182/blood.V120.21.2793.2793
Published: 2012
Journal Articles

Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib: 36-Month Minimum Follow-up Update

Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Dong-Wook Kim, Anna G Turkina, Zhi-Xiang Shen, H. Jean Khoury, Tim H Brümmendorf, Philippe Schafhausen, Edo Vellenga, Ricardo Pasquini, Vikram Mathews, Tamas Masszi, Simon Durrant, Kimmo Porkka, MD, PhD, Eric Leip, Virginia Kelly, Nadine Besson, Carlo Gambacorti-Passerini
Journal: Blood
Blood (2012) 120 (21): 3779.
https://doi.org/10.1182/blood.V120.21.3779.3779
Published: 2012
Journal Articles

Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Failure with Imatinib Plus Dasatinib and/or Nilotinib: 24-Month Minimum Follow-up Update

H. Jean Khoury, MD, Carlo Gambacorti-Passerini, Hagop M. Kantarjian, MD, Dong-Wook Kim, David Marin, Pedro E Dorlhiac-Llacer, Andrey Zaritskey, Juan Navarro, Eduardo O Bullorsky, Sarit Assouline, Eric Leip, Virginia Kelly, Kathleen Turnbull, Nadine Besson, Jorge E Cortes, MD
Journal: Blood
Blood (2012) 120 (21): 3785.
https://doi.org/10.1182/blood.V120.21.3785.3785
Published: 2012
Journal Articles

Pharmacokinetics and Tolerability of Bosutinib in Asian Versus Non-Asian Patients with Philadelphia Chromosome–Positive Leukemia

Poe-Hirr Hsyu, Karin Gogat, Ladan Duvillie, Virginia Kelly, Nadine Besson
Journal: Blood
Blood (2012) 120 (21): 4440.
https://doi.org/10.1182/blood.V120.21.4440.4440
Published: 2012
Journal Articles

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

Clinical Trials & Observations
H. Jean Khoury, Jorge E. Cortes, Hagop M. Kantarjian, Carlo Gambacorti-Passerini, Michele Baccarani, Dong-Wook Kim, Andrey Zaritskey, Athena Countouriotis, Nadine Besson, Eric Leip, Virginia Kelly, Tim H. Brümmendorf
Journal: Blood
Blood (2012) 119 (15): 3403–3412.
https://doi.org/10.1182/blood-2011-11-390120
Published: 2012
Journal Articles

Activity of Bosutinib by Baseline and Emergent Mutation Status in Philadelphia Chromosome–Positive Leukemia Patients with Resistance or Intolerance to Other Tyrosine Kinase Inhibitors

H. Jean Khoury, Jorge E Cortes, Carlo Gambacorti-Passerini, MD, Dong-Wook Kim, Andrey Zaritskey, Andreas Hochhaus, MD, Eric Leip, Nadine Besson, Virginia Kelly, Tim H Brümmendorf
Journal: Blood
Blood (2011) 118 (21): 110.
https://doi.org/10.1182/blood.V118.21.110.110
Published: 2011
Journal Articles

Bosutinib Safety Profile and Management of Toxicities in Leukemia Patients with Resistance or Intolerance to Imatinib and Other Tyrosine Kinase Inhibitors

Hagop M Kantarjian, Jorge E Cortes, Dong-Wook Kim, H. Jean Khoury, Tim H Brümmendorf, Kimmo Porkka, MD, PhD, Giovanni Martinelli, MD, Simon Durrant, Eric Leip, Nadine Besson, Virginia Kelly, Carlo Gambacorti-Passerini, MD
Journal: Blood
Blood (2011) 118 (21): 2760.
https://doi.org/10.1182/blood.V118.21.2760.2760
Published: 2011
Journal Articles

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

Clinical Trials & Observations
Jorge E. Cortes, Hagop M. Kantarjian, Tim H. Brümmendorf, Dong-Wook Kim, Anna G. Turkina, Zhi-Xiang Shen, Ricardo Pasquini, H. Jean Khoury, Steven Arkin, Angela Volkert, Nadine Besson, Richat Abbas, Junyuan Wang, Eric Leip, Carlo Gambacorti-Passerini
Journal: Blood
Blood (2011) 118 (17): 4567–4576.
https://doi.org/10.1182/blood-2011-05-355594
Published: 2011
Includes: Supplemental data
Journal Articles

Clinical Activity of Bosutinib by Mutational Status In Patients with Previously Treated Philadelphia Chromosome–positive Leukemias.

Carlo Gambacorti-Passerini, H. Jean Khoury, Helio Pinczowski, Tamas Masszi, MD, PhD, Dong-Wook Kim, MD, Maria Zanichelli, Giovanni Martinelli, Virginia Kelly, Nadine Besson, Trevor McMullan, Tim H. Brummendorf, MD, Jorge E. Cortes
Journal: Blood
Blood (2010) 116 (21): 3434.
https://doi.org/10.1182/blood.V116.21.3434.3434
Published: 2010
Journal Articles

Bosutinib as Third-Line Treatment for Chronic Phase Chronic Myeloid Leukemia Following Failure of Second-Line Therapy with Dasatinib or Nilotinib

H. Jean Khoury, Dong-Wook Kim, MD, Andrey Zaritskey, Carlo Gambacorti-Passerini, Andreas Hochhaus, Juan Navarro, Aaron P. Rapoport, Pedro Enrique Dorlhiac-Llacer, Maria Zanichelli, Virginia Kelly, Nadine Besson, Trevor McMullan, Hagop M. Kantarjian, Jorge E. Cortes
Journal: Blood
Blood (2010) 116 (21): 892.
https://doi.org/10.1182/blood.V116.21.892.892
Published: 2010